ARHGAP36: A new survival predictor for neuroblastoma patients

Cancer frequently co-opts fundamental developmental processes, such as neural crest migration, to drive malignancy and metastasis. Lineage-specific transcription factors, critical for these morphogenetic events, often emerge as key drivers of oncogenesis. One such example is the forkhead transcription factor FOXC1, whose gain of function is a feature across various cancers and consistently associates with an unfavorable prognosis.¹

Researchers at the University of Cambridge and the University of Oxford investigated the mechanistic underpinnings of FOXC1 activity, focusing on its transcriptional targets and their implications for cancer progression. They employed a multi-modal approach, combining RNA sequencing, ChIP sequencing, and CRISPR interference in murine cells to map FOXC1's regulatory landscape. The team then validated key findings in a large cohort of human neuroblastoma patients, a malignancy known for its neural crest origins.¹

FOXC1's unexpected target: ARHGAP36

The investigators found that FOXC1 directly binds to a specific locus within a region of closed chromatin to induce the expression of ARHGAP36.¹ This was a significant discovery, as ARHGAP36 is a tissue-specific inhibitor of protein kinase A (PKA). PKA itself is a core inhibitor of the Hedgehog (Hh) pathway, a critical signaling cascade in development and a known driver of numerous cancers. The implication was clear: FOXC1's induction of ARHGAP36 expression would, by inhibiting PKA, lead to increased Hh pathway activity.¹

The team further elucidated this mechanism. They showed that the function of Sufu, a PKA substrate and another essential Hh pathway inhibitor, was similarly impaired by the increased ARHGAP36 activity. This dual inhibition of PKA and Sufu, both negative regulators of the Hh pathway, resulted in a substantial increase in Hh pathway output. This heightened Hh activity exhibited a concerning phenotype: it became resistant to pharmacological inhibition of Smoothened (Smo), a key transducer in the Hh pathway. This resistance to Smo inhibition is a characteristic often associated with more aggressive cancers, suggesting a potential mechanism for therapeutic evasion.¹

The initial mechanistic studies were conducted in murine cells, providing a foundational understanding of the FOXC1-ARHGAP36-PKA-Hh axis. But the critical question remained: how did this translate to human malignancy, specifically neuroblastoma? The researchers extended their investigation to a large cohort of 1348 neuroblastoma patients to assess the clinical relevance of their findings.¹

ARHGAP36 as a prognostic marker in neuroblastoma

The analysis of the neuroblastoma patient cohort revealed a counterintuitive but clinically significant correlation: high levels of ARHGAP36 expression were predictive of improved 5-year survival. This finding stands in stark contrast to the expectation that increased Hh pathway activity, typically associated with aggressive cancers, would correlate with a worse prognosis. The study identified ARHGAP36 as a novel transcription factor that enhances Hh expression, one that induces Hh activity in multiple tissues during development.¹

This suggests a more complex role for the Hh pathway and its modulators in neuroblastoma than previously understood. While FOXC1 gain of function is generally linked to unfavorable prognoses in diverse cancers, its induction of ARHGAP36 in neuroblastoma appears to operate within a context where the resulting Hh pathway modulation leads to a better outcome. This could imply that the specific context of Hh activation, or the downstream effectors engaged by ARHGAP36, might dictate its prognostic impact.¹

The study establishes a model where increased FOXC1 levels, acting via ARHGAP36 and subsequent PKA inhibition, dysregulate multiple facets of Hh signaling. This dysregulation, while increasing Hh output, does not uniformly lead to a worse prognosis in neuroblastoma. The resistance to Smoothened inhibition observed in murine models, a hallmark of aggressive cancers, further complicates the picture. It suggests that while the pathway is more active and less responsive to canonical inhibitors, the overall effect on tumor biology in neuroblastoma might be protective, or at least not uniformly detrimental.¹

The researchers did not explicitly detail the specific mechanisms by which increased Hh activity, when mediated by ARHGAP36, might lead to improved survival. This remains an open question. It is possible that the specific type of Hh activation induced by ARHGAP36 might trigger differentiation pathways, reduce metastatic potential, or enhance immune surveillance in neuroblastoma, rather than simply promoting unchecked proliferation. The Oxford Handbook of Oncology provides a comprehensive overview of such complex signaling pathways in cancer.¹

Where the data leaves us

The study's strength lies in its comprehensive mechanistic dissection, moving from gene regulation in murine models to clinical validation in a large human cohort. The use of RNA-sequencing, ChIP-sequencing, and CRISPR interference provides robust evidence for the FOXC1-ARHGAP36 regulatory axis. The large patient cohort (N=1348) lends considerable weight to the prognostic significance of ARHGAP36 expression in neuroblastoma.¹

But the study was not designed to explain the paradox of increased Hh activity correlating with improved survival. While it identifies the predictive factor, the underlying biological reasons for this inverse relationship are not fully elucidated. The resistance to Smoothened inhibition, a finding from the murine models, also needs further exploration in human neuroblastoma cells to understand its clinical implications. It is unclear if this resistance translates to clinical non-response to Hh inhibitors in patients with high ARHGAP36.¹

The research also focused on ARHGAP36 as a predictive factor for 5-year survival. Future studies would benefit from exploring its role in other clinical endpoints, such as disease-free survival, progression-free survival, and response to specific therapies. The heterogeneity of neuroblastoma, with different genetic subtypes and risk stratifications, also warrants further investigation into how ARHGAP36 expression behaves across these distinct patient groups.¹

The study provides compelling evidence for the relevance of the FOXC1-ARHGAP36-PKA axis to a common neural crest-derived malignancy. It identifies a novel transcription factor that enhances ARHGAP36 expression, which in turn induces Hh activity. The model of how increased FOXC1 levels, via ARHGAP36 and PKA inhibition, dysregulate multiple facets of Hh signaling is well-established. The clinical correlation with improved survival, however, demands deeper biological investigation to reconcile the mechanistic findings with the observed patient outcomes.¹